American Century Companies Inc. Has $300,000 Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

American Century Companies Inc. trimmed its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 14.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,541 shares of the company’s stock after selling 1,392 shares during the period. American Century Companies Inc.’s holdings in IDEAYA Biosciences were worth $300,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in shares of IDEAYA Biosciences during the second quarter worth about $41,000. Covestor Ltd boosted its position in shares of IDEAYA Biosciences by 9,225.0% during the first quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after buying an additional 1,107 shares during the period. Comerica Bank boosted its position in shares of IDEAYA Biosciences by 723.5% during the first quarter. Comerica Bank now owns 1,507 shares of the company’s stock worth $66,000 after buying an additional 1,324 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new position in shares of IDEAYA Biosciences during the first quarter worth about $67,000. Finally, Daiwa Securities Group Inc. raised its holdings in IDEAYA Biosciences by 637.9% during the second quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company’s stock worth $68,000 after acquiring an additional 1,684 shares in the last quarter. 98.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently issued reports on IDYA. JPMorgan Chase & Co. dropped their target price on IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Citigroup dropped their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th. Stifel Nicolaus upped their target price on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a report on Tuesday, September 10th. BTIG Research upped their price objective on IDEAYA Biosciences from $55.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, July 9th. Finally, Wedbush dropped their price objective on IDEAYA Biosciences from $54.00 to $52.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 24th. Twelve equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences has an average rating of “Buy” and an average price target of $56.00.

IDEAYA Biosciences Trading Up 2.5 %

IDEAYA Biosciences stock opened at $29.97 on Friday. IDEAYA Biosciences, Inc. has a 12 month low of $23.41 and a 12 month high of $47.74. The stock’s 50 day moving average is $36.73 and its 200-day moving average is $38.78. The company has a market capitalization of $2.27 billion, a price-to-earnings ratio of -14.91 and a beta of 0.84.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). IDEAYA Biosciences had a negative return on equity of 20.52% and a negative net margin of 483.05%. During the same period last year, the company posted ($0.50) EPS. As a group, equities research analysts predict that IDEAYA Biosciences, Inc. will post -2.51 earnings per share for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.